<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Synthetic angiotensin II: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Synthetic angiotensin II: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Synthetic angiotensin II: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="116219" href="/d/html/116219.html" rel="external">see "Synthetic angiotensin II: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50984000"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Giapreza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50876399"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vasoactive Agent</li></ul></div>
<div class="block doa drugH1Div" id="F50984012"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dbc3d915-e72b-4ff0-a55d-9b30bb0869da">Septic shock or other vasodilatory shock states</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock or other vasodilatory shock states (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV: </b>Initial: 10 to 20 ng/kg/minute; titrate dose by up to 10 to 15 ng/kg/minute every 5 minutes based on goal MAP. Once shock has sufficiently improved, decrease dose by ≤15 ng/kg/minute every 5 to 15 minutes based on response. Doses as low as 1.25 ng/kg/minute may be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28528561','lexi-content-ref-32882250','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28528561','lexi-content-ref-32882250','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum initial dose:<b> IV:</b> 80 ng/kg/minute during the first 3 hours of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum maintenance dose:<b> IV:</b> 40 ng/kg/minute.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991173"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustments are expected; angiotensin II clearance is not dependent on kidney function.</p></div>
<div class="block doha drugH1Div" id="F50988178"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustments are expected; angiotensin II clearance is not dependent on hepatic function.</p></div>
<div class="block doe drugH1Div" id="F50984013"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F50889196"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reaction incidence reported in adults on concomitant vasopressor therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Thromboembolic disease (13%; deep vein thrombosis [4%])</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral ischemia (4%), tachycardia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (6%), hyperglycemia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Busse 2017), cardiac arrhythmia (including atrial fibrillation and sinus tachycardia) (Wieruszewski 2021), orthostatic dizziness (Busse 2017), orthostatic hypotension (Busse 2017), worsening of heart failure (Busse 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Mesenteric ischemia (Wieruszewski 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (Wieruszewski 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (Busse 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Exacerbation of asthma (Busse 2017; Millar 1995)</p></div>
<div class="block coi drugH1Div" id="F50876398"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F50984004"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchoconstriction: Exacerbation of asthma has been reported; use with caution (Busse 2017; Millar 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Angiotensin II is an irritant with vesicant-like properties; avoid extravasation (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Exacerbation of heart failure has been reported; use with caution (Busse 2017; Cohn 1965).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombosis: Arterial and venous thrombotic and thromboembolic events have been reported; use concurrent venous thromboembolism prophylaxis.</p></div>
<div class="block foc drugH1Div" id="F51083206"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Giapreza: 0.5 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Giapreza: 2.5 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F50984001"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51131765"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Giapreza Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/mL (per mL): $540.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/mL (per mL): $1,944.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F50984016"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV: </b>Administer as a continuous IV infusion via an infusion pump. Central line administration is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Irritant with vesicant-like properties; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate phentolamine antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose IV through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F50876397"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Septic shock or other vasodilatory shock states: </b>To increase BP in adults with septic or other distributive shock.</p></div>
<div class="block mst drugH1Div" id="F50983999"><span class="drugH1">Medication Safety Issues</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sound-alike/look-alike issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Angiotensin II may be confused with angiotensin II receptor blockers</p>
<p style="text-indent:-2em;margin-left:4em;">Angiotensin II may be confused with angiotensin converting enzyme inhibitors</p>
<p style="text-indent:-2em;margin-left:4em;">ATII (abbreviation for Angiotensin II) may be confused with ATIII (abbreviation for Antithrombin)</p></div>
<div class="block cyt drugH1Div" id="F50907333"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50907330"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May diminish the therapeutic effect of Angiotensin II.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the therapeutic effect of Angiotensin II.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F50984002"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. When treatment for septic or other disruptive shock is needed, delaying treatment due to pregnancy increases the risk of maternal and fetal morbidity and mortality.</p></div>
<div class="block brc drugH1Div" id="F50984003"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if angiotensin II is present in breast milk following administration of this preparation.</p></div>
<div class="block mop drugH1Div" id="F50984018"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP (or mean arterial pressure), heart rate, signs and symptoms of thromboembolism, platelet count, lactate.</p></div>
<div class="block pha drugH1Div" id="F50984008"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Naturally occurring peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and increases aldosterone release, which raises blood pressure.</p></div>
<div class="block phk drugH1Div" id="F50984009"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized by aminopeptidase A and angiotensin converting enzyme 2 to angiotensin-(2-8) [angiotensin III] and angiotensin-(1-7), respectively in plasma, erythrocytes and many major organs.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: &lt;1 minute</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 5 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52949334"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Giapreza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Giapreza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Giapreza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Giapreza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Giapreza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Giapreza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28489648">
<a name="28489648"></a>Busse LW, Wang XS, Chalikonda DM, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety. <i>Crit Care Med</i>. 2017;45(8):1285-1294. doi:10.1097/CCM.0000000000002441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/synthetic-angiotensin-ii-drug-information/abstract-text/28489648/pubmed" id="28489648" target="_blank">28489648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14332162">
<a name="14332162"></a>Cohn JN, Luria MH. Studies in clinical shock and hypotension. II. Hemodynamic effects of norepinephrine and angiotensin. <i>J Clin Invest.</i> 1965;44(9):1494-1504. doi:10.1172/JCI105256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/synthetic-angiotensin-ii-drug-information/abstract-text/14332162/pubmed" id="14332162" target="_blank">14332162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LaJolla.1">
<a name="LaJolla.1"></a>Giapreza (angiotensin II) [prescribing information]. San Diego, CA; La Jolla Pharmaceutical Company: December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28528561">
<a name="28528561"></a>Khanna A, English SW, Wang XS, et al; ATHOS-3 Investigators. Angiotensin II for the treatment of vasodilatory shock. <i>N Engl J Med</i>. 2017;377(5):419-430. doi:10.1056/NEJMoa1704154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/synthetic-angiotensin-ii-drug-information/abstract-text/28528561/pubmed" id="28528561" target="_blank">28528561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8620948">
<a name="8620948"></a>Millar EA, Nally JE, Thomson NC. Angiotensin II potentiates methacholine-induced bronchoconstriction in human airway both in vitro and in vivo. <i>Eur Respir J.</i> 1995;8(11):1838-1841. doi:10.1183/09031936.95.08111838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/synthetic-angiotensin-ii-drug-information/abstract-text/8620948/pubmed" id="8620948" target="_blank">8620948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/synthetic-angiotensin-ii-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32882250">
<a name="32882250"></a>Wieruszewski PM, Wittwer ED, Kashani KB, et al. Angiotensin II infusion for shock: a multicenter study of postmarketing use. <i>Chest</i>. 2021;159(2):596-605. doi:10.1016/j.chest.2020.08.2074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/synthetic-angiotensin-ii-drug-information/abstract-text/32882250/pubmed" id="32882250" target="_blank">32882250</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 116178 Version 56.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
